These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 19796079)

  • 1. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
    Mitrpant C; Fletcher S; Iversen PL; Wilton SD
    J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
    J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
    Takeshima Y; Yagi M; Wada H; Matsuo M
    Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
    Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
    Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced dystrophin exon skipping in human muscle explants.
    McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
    Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances of treatment for Duchenne muscular dystrophy with exon skipping].
    Yang J; Zhang C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Aug; 28(4):406-8. PubMed ID: 21811980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
    van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
    Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing splice-switching oligomer sequences using 2'-O-methyl phosphorothioate chemistry.
    Adkin C; Fletcher S; Wilton SD
    Methods Mol Biol; 2012; 867():169-88. PubMed ID: 22454061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.